Search Page

1

Cite

Share

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S; Tysabri® Observational Program (TOP) Investigators. Trojano M, et al. Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2. Mult Scler Relat Disord. 2018. PMID: 29860197 Free article.

Cite

Share

2

Cite

Share

A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.

Grimaldi L, Barkhof F, Beelke M, Burton J, Holmoy T, Hupperts R, Killestein J, Rieckmann P, Schluep M, Smolders J; SOLAR Study Group. Grimaldi L, et al. Neurology. 2012 Mar 13;78(11):841. doi: 10.1212/01.wnl.0000413180.13413.ce. Neurology. 2012. PMID: 22411961 No abstract available.

Cite

Share

3

Cite

Share

Isolated ring-finger myoclonus.

Schramm A, Cursiefen S, Schröder R. Schramm A, et al. Among authors: cursiefen s. J Neurol. 2011 Jun;258(6):1164-5. doi: 10.1007/s00415-010-5827-6. Epub 2010 Nov 23. J Neurol. 2011. PMID: 21104266 No abstract available.

Cite

Share

4

Cite

Share

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V. Putzki N, et al. Among authors: cursiefen s. Eur J Neurol. 2010 Jan;17(1):31-7. doi: 10.1111/j.1468-1331.2009.02728.x. Epub 2009 Jul 9. Eur J Neurol. 2010. PMID: 19614963 Clinical Trial.

Cite

Share

5

Cite

Share

[Current use of immunoglobulins in neurology].

Cursiefen S, Mäurer M. Cursiefen S, et al. Nervenarzt. 2008 Sep;79 Suppl 2:67-74; quiz 75-6. doi: 10.1007/s00115-008-2461-y. Nervenarzt. 2008. PMID: 18679643 Review. German.

Cite

Share

6

Cite

Share

Assessment of cardiovascular autonomic function in myotonic dystrophy type 2 (DM2/PROMM).

Flachenecker P, Schneider C, Cursiefen S, Ricker K, Toyka KV, Reiners K. Flachenecker P, et al. Among authors: cursiefen s. Neuromuscul Disord. 2003 May;13(4):289-93. doi: 10.1016/s0960-8966(02)00277-8. Neuromuscul Disord. 2003. PMID: 12868497

Cite

Share

7

Cite

Share

Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.

Cursiefen S, Flachenecker P, Toyka KV, Rieckmann P. Cursiefen S, et al. Eur Neurol. 2000;43(3):186-7. doi: 10.1159/000008163. Eur Neurol. 2000. PMID: 10765063 No abstract available.

Cite

Share

8

Cite

Share

Migraine and tension headache in high-pressure and normal-pressure glaucoma.

Cursiefen C, Wisse M, Cursiefen S, Jünemann A, Martus P, Korth M. Cursiefen C, et al. Among authors: cursiefen s. Am J Ophthalmol. 2000 Jan;129(1):102-4. doi: 10.1016/s0002-9394(99)00289-5. Am J Ophthalmol. 2000. PMID: 10653426

Cite

Share

9

Cite

Share

[Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients].

Cursiefen S, Flachenecker P, Rieckmann P, Toyka KV. Cursiefen S, et al. Nervenarzt. 1999 Aug;70(8):723-31. doi: 10.1007/s001150050501. Nervenarzt. 1999. PMID: 10483572 Review. German.

Cite

Share